ISET® for ImmunoTheranostics



  • 30 metastatic non-small-cell lung cancer patients
  • Cytopathological analysis identified CCC in 28 patients (93,3%)
  • By CK+/CD45- IF, epithelial CTC were detected in 17 patients (56,7%)
  • Median progression-free survival (PFS) was significantly shorter in patients with >3 PD-1(+) CTCs at baseline compared with those with <3 PD-1(+) CTCs (p = 0.022) as well as in patients with >1 Giemsa-positive tumor cells (p = 0.025).

  • 106 lung adenocarcinoma patients (stages III-IV)
  • Cytopathological analysis identified CCC in 80 patients (75%)
  • 93% concordance of PD-L1 expression between tissue and CTCs (Sensitivity=55%; Specificity=100%)